CD1D and cancer: Expression of CD1C enhances human invariant NKT cell activation by α-GalCer, which indicated that B cell neoplasias that co-express CD1C and CD1D may be particularly susceptible to α-GSL therapy, and cancer vaccines using α-GSLs as adjuvants may be most effective when presented by CD1C+ antigen-presenting cells (PMID: 23885215).